SPDR SSGA Multi-Asset Real Return ETF logo

SPDR SSGA Multi-Asset Real Return ETF (RLY)

Market Closed
8 Dec, 20:00
ARCA ARCA
$
31. 59
-0.23
-0.72%
$
594.48M Market Cap
1.39% Div Yield
77,999 Volume
$ 31.82
Previous Close
Day Range
31.53 31.71
Year Range
25.63 32.05
Want to track RLY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

RLY closed today lower at $31.59, a decrease of 0.72% from yesterday's close, completing a monthly decrease of -1.22% or $0.39. Over the past 12 months, RLY stock gained 15.97%.
RLY pays dividends to its shareholders, with the most recent payment made on Sep 29, 2025. The next estimated payment will be in In 3 weeks on Dec 29, 2025 for a total of $0.09922.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on ARCA (USD).

RLY Chart

Similar

Invesco S&P SmallCap Momentum ETF
$ 73.22
-0.19%
BondBloxx Bloomberg Six Month Target Duration US Treasury ETF
$ 50.27
-0.02%
iShares Future AI & Tech ETF
$ 49.58
+0.12%
ROBO Global Robotics & Automation Index ETF
$ 70.91
-0.08%
RWR
SPDR Dow Jones REIT ETF
$ 99.24
-1.07%
Relay Therapeutics Is A Buy For Its Superb Safety Data

Relay Therapeutics Is A Buy For Its Superb Safety Data

Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608's phase 1/2 trial data demonstrates higher response rates and significantly lower toxicity compared to existing therapies like alpelisib and inavolisib. The Eli Lilly acquisition of STX-478 from Scorpion Therapeutics highlights the value of allosteric PI3Kα inhibitors, positioning RLAY as undervalued and ahead in clinical development.

Seekingalpha | 1 month ago
Relay Therapeutics: A Precision Oncology Play Worth The Risk

Relay Therapeutics: A Precision Oncology Play Worth The Risk

Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns about expense control and sustainable cash flow. Out-licensing RLY-4008 to Elevar Therapeutics secures up to $500 million in milestones, allowing RLAY to concentrate on RLY-2608's clinical trials.

Seekingalpha | 9 months ago
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion

Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion

Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast cancer patients. Key upcoming milestones for RLY-2608 program includes presenting data at the San Antonio Breast Cancer Symposium in December 2024 and initiating a phase 3 study in 2025. Expansion opportunities of the RLY-2608 program includes two triplet regimens targeting 1st-line PI3Ka-mutant HR+/HER2- breast cancer patients and phase 1 study for tumors with vascular formations starting in Q1 2025.

Seekingalpha | 1 year ago

SPDR SSGA Multi-Asset Real Return ETF (RLY) FAQ

What is the stock price today?

The current price is $31.59.

On which exchange is it traded?

SPDR SSGA Multi-Asset Real Return ETF is listed on ARCA.

What is its stock symbol?

The ticker symbol is RLY.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 1.39%.

What is its market cap?

As of today, the market cap is 594.48M.

Has SPDR SSGA Multi-Asset Real Return ETF ever had a stock split?

No, there has never been a stock split.

SPDR SSGA Multi-Asset Real Return ETF Profile

ARCA Exchange
US Country

Overview

The company appears to specialize in investment management with a clear focus on diversifying its investment portfolio across various asset classes to hedge against inflation and capitalize on potential growth opportunities. The strategic allocation towards a mix of inflation-protected securities, real estate, commodities, infrastructure, and natural resources companies underlines a comprehensive approach to asset management. By investing in Exchange-Traded Products (ETPs) that provide exposure to these asset classes, the company aims to offer investors a blend of income generation, capital appreciation, and inflation protection. This strategy signifies a robust investment framework designed to navigate through varying economic environments while seeking sustainable returns.

Products and Services

  • Inflation Protected Securities:

    Investments in securities issued by the United States government that are designed to protect against inflation. This typically involves Treasury Inflation-Protected Securities (TIPS), which adjust in response to inflation as measured by the Consumer Price Index, thereby offering a real rate of return guaranteed by the U.S. government.

  • Real Estate Securities:

    Focusing on both domestic and international real estate securities, the company invests in stocks or ETPs related to the real estate market. This can include investments in Real Estate Investment Trusts (REITs) which provide exposure to commercial, residential, and industrial real estate sectors, offering potential income through dividends and capital appreciation.

  • Commodities:

    Exposure to commodities through ETPs allows the company to invest in physical commodities like metals, energy, and agricultural products or in commodity-related companies. This diversification helps in hedging against inflation and taking advantage of growth in the commodity markets.

  • Infrastructure Companies:

    Investments in publicly-traded domestic and international infrastructure companies. These can include enterprises involved in the construction, management, or operation of infrastructure assets such as roads, bridges, ports, and utilities. Infrastructure investments often provide stable cash flows and have a potential inflation protection component.

  • Natural Resources and Commodities Businesses:

    Focusing on publicly-traded companies involved in the natural resources sector or commodities businesses. This can include enterprises engaged in the extraction, production, or sale of natural resources like oil, gas, metals, and minerals. Investments in this area often seek to leverage growth in the global demand for natural resources.

Contact Information

Address: -
Phone: NA